Vanda Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VANDA PHARMS INC
VANDA PHARMS INC has six approved drugs.
There are fifty-four US patents protecting VANDA PHARMS INC drugs.
There are four hundred and sixty-four patent family members on VANDA PHARMS INC drugs in forty-five countries and fourteen supplementary protection certificates in thirteen countries.
Summary for Vanda Pharms Inc
| International Patents: | 464 |
| US Patents: | 54 |
| Tradenames: | 6 |
| Ingredients: | 5 |
| NDAs: | 6 |
Drugs and US Patents for Vanda Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | BYSANTI | milsaperidone | TABLET;ORAL | 220358-003 | Feb 20, 2026 | RX | Yes | No | 12,606,869 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Vanda Pharms Inc | PONVORY | ponesimod | TABLET;ORAL | 213498-003 | Mar 18, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | AB | RX | Yes | Yes | 11,850,229 | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Vanda Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | HETLIOZ LQ | tasimelteon | SUSPENSION;ORAL | 214517-001 | Dec 1, 2020 | 5,856,529 | ⤷ Start Trial |
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-007 | May 6, 2009 | RE39198 | ⤷ Start Trial |
| Vanda Pharms Inc | PONVORY | ponesimod | TABLET;ORAL | 213498-008 | Mar 18, 2021 | 8,273,779 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for VANDA PHARMS INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 20 mg | ➤ Subscribe | 2018-01-31 |
| ➤ Subscribe | Capsules | 20 mg | ➤ Subscribe | 2018-01-31 |
| ➤ Subscribe | Tablets | 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, & 12 mg | ➤ Subscribe | 2013-05-06 |
International Patents for Vanda Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2021204784 | ⤷ Start Trial |
| South Korea | 20210067980 | ⤷ Start Trial |
| South Korea | 20200022543 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Vanda Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3256125 | PA2022505 | Lithuania | ⤷ Start Trial | PRODUCT NAME: PONEZIMODAS; REGISTRATION NO/DATE: EU/1/21/1550 20210519 |
| 3256125 | LUC00262 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: PONESIMOD (NOM IUPAC : (R)-5-(3-CHLORO-4-(2,3-DIHYDROXY-PROPOXY)-BENZ(Z)YLIDENE)-2-((Z)-PROPYLIMINO)-3-O-TOLYL-THIAZOLIDIN-4-ONE), ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/21/1550 20210521 |
| 3256125 | SPC/GB22/026 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: PONESIMOD ((R)-5-(3-CHLORO-4-(2,3-DIHYDROXY-PROPOXY)-BENZ(Z)YLIDENE)-2-((Z)-PROPYLIMINO)-3-O-TOLYL-THIAZOLIDIN-4-ONE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU1/21/1550 (FOR NI) 20210521; UK FURTHER MAS ON IPSUM 20210521 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
